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The present study aimed to analyze changes in the inci-
dence of and pathogens associated with bacteremias and the
development of microbial resistance during two different
prophylactic strategies in adult recipients of allogeneic
hematopoietic stem cell transplantation (HSCT) at Memorial
Sloan-Kettering Cancer Center.
Methods: This was an observational cohort study of 1,138
consecutive adult HSCT from 2000-2011. Bacteremias
occurring from day -7 to þ100 post HSCT were entered into
a computerized database. Beginning November 2005, all
patients except those receiving nonmyeloablative-condi-
tioning regimens were given vancomycin prophylaxis from
day -2 through day þ7. Fluoroquinolone (FQ) prophylaxis
was initiated in November 2006. We compared the overall
incidence of bacteremia, changing spectrum of the organ-
isms, and the resistance pattern between 2000-2005 (period
A) and 2006-2011 (period B).
Results: During the study period, 312 (28%) patients had 363
bacteremic episodes with 392 pathogens isolated. The
median onset of ﬁrst episode was 7 days post transplant, and
62% of the episodes occurred before neutrophil recovery. The
incidence of gram-positive bacteria (GPB) and gram-negative
rod (GNR) bacteremia was 19% and 15%, respectively.
Enterococcus faecium was the most commonly isolated GPB
(46%), followed by viridans group streptococci (17%), while
Escherichia coli was the most common GNR (26%). Vanco-
mycin-resistant enterococci comprised the majority of
enterococcal isolates (81% in period A and 90% in period B,Etiology of bacteremias pre- and post-antibiotic prophylaxis








N (%)* N (%)*
Gram positive bacteria 219
Coagulase-negative
staphylococci
21 (5.3) 32 (4.3) 53
Enterococcus faecium 36 (9.1) 64 (8.6) 100
Enterococcus faecalis 7 (1.8) 5 (0.7) 12
Viridans group
streptococci
31 (7.8) 6 (0.8) 37
Staphylococcus aureus 5 6 11
Corynebacterium JK 3 1 4
Bacillus spp. 1 0 1
Gram-negative bacteria 173
Enterobacteriaceae total 37 (9.3) 79 (10.6) 116
Escherichia coli 16 29 45
Klebseilla spp. 14 29 43
Enterobacter spp. 7 13 20
Serratia spp. 0 8 8
Non-fermenter GNR 16 (4) 25 (3.4) 41




Acinetobacter spp. 8 7 15
Fusobacterium spp. 6 2 8
Other GNRy 5 4 9
Total number of allo-HSCT 397 742 1138
* % number of organisms/total allo-HSCT recipients during that period.
y Neisseria spp 1, Bacteroidesfragilis 1, Achromobacter xylosoxidans 1,
Hemophilus parainﬂuenzae 1, Roseomonas spp. 1, Proteus mirabilis 1,
Moraxella spp 1, Leuconostoc spp. 1. Clostridium spp 1.P¼0.2011). Eighty-nine percent of the Viridans streptococcal
bacteremias (VSB) and 60% of the GNR bacteremias occurred
before neutrophil recovery. The overall incidence of bacter-
emia decreased signiﬁcantly from 32% in period A to 25% in
period B (P¼0.005). Viridans group streptococci comprised
31 of 168 (18%) organisms in period A compared to 6 of 224
(3%) in period B (P <0.0001). The incidence of enterococcal
bacteremia remained stable (11% versus 9%, p¼0.47). There
was no change in the incidence of GNR bacteremia during
the study period (17% in 2000 e 2006 and 14% in 2007 e
2011, p¼0.27). Among GNR, the rate of FQ resistance was 39%
and was unchanged between the two periods.
Conclusions: Duringa12-yearperiod, theoverall incidenceof
bacteremia decreased. The decrease was mainly due to the
dramatic decrease of VSB after institution of vancomycin for
prophylaxis. The incidence of GNR and VRE bacteremia
remained stable in the periods pre and post FQ prophylaxis.
The rate of FQ resistance among GNR was also unchanged in
the two periods. Continued surveillance is necessary to iden-
tify changes in local epidemiology, to reevaluate prophylactic
regimens and to guide new empiric-therapy schemes.
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Background: BK virus (BKV) associated hemorrhagic cystitis
(HC) following allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) has been increasingly reported.
However, there is less information about diagnosis and
treatment. The purpose of this study is to clarify the signif-
icance of viral subtypes in the pathogenesis of BKV-HC in
Japanese subjects.
Methods: Urinary decoy cells compatible with BKV reac-
tivation were examined in patients every week as post-HSCT
screening. The real-time quantitative PCR (qPCR) for BKV and
adenovirus (ADV) were performed on urine samples when
patients developed HC and/or had positive decoy cells. BKV
subtypes (I-IV) were determined through viral DNA
sequencing in each patients with positive BKV qPCR (>2x102
copies/ml).
Results: A total of 84 allo-HSCTs were performed between
July 2010 and April 2012 (Figure 1). Of the 31 patients (pts)
whom only BKV reactivation was detected, 11 developed HC.
BKV subtypes were determined in these 31 pts (Ia: n¼2, Ib-1:
n¼2, Ic: n¼16, III: n¼8, and IVb-1: n¼3). Interestingly, BKV
subtype III was found in 6 of 11 pts with BKV-HC. There was
no direct correlation between development of HC and viral
load (HC vs No-HC: 1.3 vs 2.0x107 copies/mL, p¼0.86). In
addition, there was no signiﬁcant association between HC
and other risk factors such as age (p¼0.45), disease status
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acute GVHD (p¼0.71). Only BKV subtype III had a statistically
signiﬁcant correlation with HC (OR: 10.8, 95%CI: 1.64-70.93,
p¼0.013).
Conclusion: BKV is ubiquitous among humans, infecting
children asymptomatically and then persisting in renal
tissue. Subtype Ic is most prevalent (>90%), followed by
subtype IV, while subtype III are rarely found in Japan. Our
data suggested the importance of BKV subtype III in the
development of BKV-HC. Further studies focused on the viral
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Background: Allogeneic hematopoietic cell transplantation
(alloHCT) is the only option for cure for many patients with
hematological malignancies such as leukemia and MDS;
however many patients, especially the older population,
cannot tolerate full-intensity ablative conditioning regimens.
Fludarabine and melphalan has been efﬁcacious as a reduced
intensity conditioning regimen for alloHCT for multiple
malignancies, but the relapse rate for this regimen remains
high. We have replaced ﬂudarabine with clofarabine,
a rationally designed second-generation purine nucleoside
analog. Clofarabine has increased immunosuppressive and
anti-leukemic activity compared to ﬂudarabine in vitro, and
we have found in a phase I study that the clofarabine/
melphalan conditioning regimen for alloHCT in patients with
acute leukemia or MDS is safe and tolerable. We hypothe-
sized that analysis of outcomes for patients treated using thisregimen would demonstrate favorable relapse rates while
maintaining a low-toxicity proﬁle.
Patients & Methods: Twenty patients with high-risk
leukemia or MDS, with a median age of 63 years, underwent
alloHCT from November 2007 until June of 2012. Patients
were treated at one of three dose levels of a clofarabine (day
-9 to day -5) and melphalan (on day -4) conditioning
regimen: 3 patients received 30 mg/m2 clofarabine and 100
mg/m2 melphalan (dose level 1), 12 patients received 40 mg/
m2 clofarabine and 100mg/m2melphalan (dose level 2), and
5 patients received 40 mg/m2 clofarabine and 140 mg/ m2
melphalan (dose level 3). The ﬁrst 16 patients were included
in a phase 1 prospective study and 4 additional patients were
treated at dose level 3 off protocol. Graft-versus-host-disease
(GVHD) prophylaxis began on day -3with the combination of
tacrolimus and sirolimus.
Results: The median follow-up for surviving patients was
28.7months (1.1 - 52.9). Overall survival at 1 year and 2 years
was 77% and 70 % respectively. Event-free survival at 1 and 2
years was the same, at 70.7% (95% CI: 52.1 - 83.2). Fifty
percent of patients experienced acute GVHD (grades I and II
only), and 69% of evaluable patients experienced chronic
GVHD. The majority of toxicities were related to the gastro-
intestinal system including elevated liver enzymes with one
patient experiencing grade 4 hepatic toxicity. Other adverse
events included renal insufﬁciency (5 patients), CNS toxicity
(2 patients), and cardiac toxicity (1 patient).
Conclusion: The combination of clofarabine and high dose
melphalan is a well tolerated conditioning regimen that
provides a durable remission and event-free survival of 70.7%
in patients with high-risk disease. We are planning to initiate
a phase 2 trial to examine the anti-leukemic activity of dose
level 3 for this clofarabine/melphalan reduced-intensity
alloHCT regimen in patients with high-risk acute myeloge-
nous leukemia.
Overall Survival and Event Free Survival Patients treated with Clo/Mel at 30/
100 (n¼3), 40/100 (n¼12), 40/140 (n¼5) Transplant Date Range: 11/28/2007-
06/28/2012.
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